Marker Therapeutics, Inc.
$1.22 $0.00 (+0.00%) 1D Market openKey Metrics
The Story So Far
LAST 6 MONTHS PRIMARY SOURCES ONLY-
Jul 24
From its Feb 3 high, the share price fell 34%.
Peak close $1.85 on Feb 3; trough close $1.22 on Jul 24. The drawdown is the fact — the chapters around it are the context.
RECEIPT: PRICE SERIES, PEAK-TO-TROUGH -34% -
Jul 16
Money rotated out of high-beta cohorts market-wide.
High-beta names lagged the blue-chips by 20.3 points over ten sessions around this date. Stocks in that cohort weren't falling alone — they fell together.
RECEIPT: ROTATION GAUGE, LIVE -
Jul 7
The stock moved +13.5% in a single session.
Sessions this size usually pair with a chapter above or below — a filing, a headline, or the whole cohort moving together.
RECEIPT: DAILY BAR, Jul 7 -
Apr 9
The stock moved +19.9% in a single session.
Sessions this size usually pair with a chapter above or below — a filing, a headline, or the whole cohort moving together.
RECEIPT: DAILY BAR, Apr 9
The story updates itself as events post · The wolf reports; you decide
Snapshot
About Marker Therapeutics, Inc.
Marker Therapeutics Inc is a clinical-stage immuno-oncology company specializing in the development and commercialization of novel T cell-based immunotherapies and peptide-based vaccines for the treatment of hematological malignancies and solid tumor indications.
Wolf Grade COMING SOON
The wolf is in training. Composite grades vs sector — profitability, health, value, momentum — arrive with the percentile engine. Methodology will be public.